@article{d1150d2d8fc74d1aaef1f130fd1bcde7,
title = "375O Final efficacy results from IMpower132: First-line atezolizumab + chemotherapy in patients with stage IV non-squamous NSCLC",
author = "M Nishio and F Barlesi and S Ball and R Bordoni and M Cobo and P Dubray-Longeras and J Goldschmidt and S Novello and FJ Orlandi and Sanborn, \{Rachel E\} and Z Szalai and G Ursol and D Mendus and L Wang and X Wen and M McCleland and T Hoang and S Phan and M Socinski",
note = "Background The Phase III IMpower132 study, evaluating first line pemetrexed plus carboplatin/cisplatin with or without atezolizumab in Stage IV non-squamous NSCLC without EGFR or ALK driver mutations, has met its PFS endpoint with an HR of 0.60 (95\% CI: 0.49, 0.72; P < 0.0001; Papadimitrakopoulou, WCLC 2018).",
year = "2020",
month = nov,
day = "1",
doi = "10.1016/J.ANNONC.2020.10.369",
language = "American English",
volume = "31",
journal = "Annals of Oncology",
issn = "1569-8041",
publisher = "Elsevier",
}